<p>Immunome（纳斯达克：IMNM - 获取免费报告）预计将在 2025 年第二季度的收益结果于 8 月 11 日星期一市场开盘前公布。分析师预计该公司将公布每股收益（$0.52）和季度收入为 103 万美元。</p>
<ul>
<li>3 只小盘股具有巨大的增长潜力</li>
</ul>
<p>Immunome（纳斯达克：IMNM - 获取免费报告）上一次公布收益结果是在 5 月 12 日星期一。该公司报告季度每股收益为（$0.52），超出市场共识预期的（$0.66）$0.14。Immunome 的净利润率为负的 1,875.21%，股本回报率为负的 71.65%。该公司在本季度的收入为 293 万美元，而分析师的预期为 46 万美元。分析师平均预计 Immunome 在当前财年的每股收益为-$2，在下一个财年的每股收益为-$3。</p>
<h2>Immunome 价格表现</h2>
<p>IMNM 的股票在星期一开盘价为$10.48。Immunome 的年低为$5.15，年高为$16.73。该公司的 50 日移动平均线为$9.38，200 日移动平均线为$8.89。该股票的市值为 9.1145 亿美元，市盈率为-3.29，贝塔值为 1.92。</p>
<h2>分析师设定新目标价</h2>
<p>几位分析师最近对该股票发表了评论。华尔街 Zen 在 5 月 22 日星期四的报告中将 Immunome 的股票评级从 “卖出” 上调至 “持有”。Wedbush 在 5 月 13 日星期二的研究报告中重申了 “跑赢大盘” 的评级，并将 Immunome 的目标价定为$21.00（从$33.00 下调）。一位分析师对该股票给予了持有评级，六位分析师对该公司给予了买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为$23.33。</p>
<p><strong>查看我们对 Immunome 的最新分析</strong></p>
<h2>内部人士买卖</h2>
<p>在相关消息中，董事 Jean Jacques Bienaime 在 6 月 3 日星期二的交易中购买了 5,000 股该公司的股票。该股票的平均购买成本为每股$9.38，总交易额为$46,900.00。购买后，该董事直接持有该公司 36,415 股股票，价值$341,572.70。这笔交易代表了他们持股比例的 15.92% 的增长。该购买在向证券交易委员会的备案中披露，相关信息可通过此链接访问。当前 8.60% 的股票由内部人士持有。</p>
<h2>对 Immunome 的对冲基金看法</h2>
<p>一位机构投资者最近增加了对 Immunome 股票的持仓。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Immunome, Inc.（纳斯达克：IMNM - 免费报告）的持股增加了 44.4%，根据其最近向证券交易委员会（SEC）的备案。该公司在本季度购买了额外的 14,398 股后，持有该公司 46,821 股股票。根据其最近的 SEC 备案，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.持有 Immunome 的股份占 0.05%，价值$316,000。机构投资者持有该公司 44.58% 的股票。</p>
<h2>Immunome 公司简介</h2>
<p>（获取免费报告）</p>
<p>Immunome, Inc.是一家生物技术公司，开发靶向癌症疗法。该公司的临床资产包括 AL102，一种正在进行的伽马分泌酶抑制剂，目前正在进行针对纤维瘤的三期临床试验；前临床资产包括 IM-1021，一种受体酪氨酸激酶样孤儿受体 1 和抗体药物偶联物，以及 IM-3050，一种针对成纤维细胞活化蛋白的放射性配体治疗；以及 IM-4320，一种抗 IL-38 免疫疗法候选药物。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票比 Immunome 更好</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>在美联储今年秋季降息之前考虑这只银行 ETF</li>
<li>特殊目的收购公司（SPAC）你需要知道的事情</li>
<li>为什么这三只市场超越者正在支持他们的回购计划</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>每个价值投资者现在应该关注的 3 只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Immunome 吗？</h2>
<p>在考虑 Immunome 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Immunome 并不在名单上。</p>
<p>虽然 Immunome 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IMNM

<p>Immunome（纳斯达克代码：IMNM）将于 8 月 11 日发布 2025 年第二季度财报，分析师预计每股亏损为 0.52 美元，收入为 103 万美元。该公司此前报告的每股亏损为 0.52 美元，超出预期。Immunome 的股票开盘价为 10.48 美元，市值为 9.1145 亿美元。分析师的评级意见不一，普遍目标价为 23.33 美元。近期内部人士购股和机构投资活动引起关注，显示出对公司在靶向癌症治疗领域增长潜力的兴趣</p>

<p>Immunome (NASDAQ:IMNM - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.52) per share and revenue of $1.03 million for the quarter.</p>
<div class="lb-trans"><p>Immunome（纳斯达克：IMNM - 获取免费报告）预计将在 2025 年第二季度的收益结果于 8 月 11 日星期一市场开盘前公布。分析师预计该公司将公布每股收益（$0.52）和季度收入为 103 万美元。</p>
</div><ul>
<li>3 Small-Cap Stocks With Big Growth Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盘股具有巨大的增长潜力</li>
</ul>
</div><p>Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14. Immunome had a negative net margin of 1,875.21% and a negative return on equity of 71.65%. The company had revenue of $2.93 million during the quarter, compared to analysts' expectations of $0.46 million. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Immunome（纳斯达克：IMNM - 获取免费报告）上一次公布收益结果是在 5 月 12 日星期一。该公司报告季度每股收益为（$0.52），超出市场共识预期的（$0.66）$0.14。Immunome 的净利润率为负的 1,875.21%，股本回报率为负的 71.65%。该公司在本季度的收入为 293 万美元，而分析师的预期为 46 万美元。分析师平均预计 Immunome 在当前财年的每股收益为-$2，在下一个财年的每股收益为-$3。</p>
</div><h2>Immunome Price Performance</h2>
<div class="lb-trans"><h2>Immunome 价格表现</h2>
</div><p>Shares of IMNM opened at $10.48 on Monday. Immunome has a one year low of $5.15 and a one year high of $16.73. The company has a 50-day moving average of $9.38 and a two-hundred day moving average of $8.89. The stock has a market cap of $911.45 million, a price-to-earnings ratio of -3.29 and a beta of 1.92.</p>
<div class="lb-trans"><p>IMNM 的股票在星期一开盘价为$10.48。Immunome 的年低为$5.15，年高为$16.73。该公司的 50 日移动平均线为$9.38，200 日移动平均线为$8.89。该股票的市值为 9.1145 亿美元，市盈率为-3.29，贝塔值为 1.92。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several analysts recently commented on the stock. Wall Street Zen upgraded shares of Immunome from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Thursday, May 22nd. Wedbush reiterated an &#34;outperform&#34; rating and issued a $21.00 target price (down from $33.00) on shares of Immunome in a research note on Tuesday, May 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $23.33.</p>
<div class="lb-trans"><p>几位分析师最近对该股票发表了评论。华尔街 Zen 在 5 月 22 日星期四的报告中将 Immunome 的股票评级从 “卖出” 上调至 “持有”。Wedbush 在 5 月 13 日星期二的研究报告中重申了 “跑赢大盘” 的评级，并将 Immunome 的目标价定为$21.00（从$33.00 下调）。一位分析师对该股票给予了持有评级，六位分析师对该公司给予了买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为$23.33。</p>
</div><p><strong>Check Out Our Latest Analysis on Immunome</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Immunome 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In related news, Director Jean Jacques Bienaime bought 5,000 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was purchased at an average cost of $9.38 per share, for a total transaction of $46,900.00. Following the purchase, the director directly owned 36,415 shares in the company, valued at $341,572.70. This trade represents a 15.92% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. 8.60% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Jean Jacques Bienaime 在 6 月 3 日星期二的交易中购买了 5,000 股该公司的股票。该股票的平均购买成本为每股$9.38，总交易额为$46,900.00。购买后，该董事直接持有该公司 36,415 股股票，价值$341,572.70。这笔交易代表了他们持股比例的 15.92% 的增长。该购买在向证券交易委员会的备案中披露，相关信息可通过此链接访问。当前 8.60% 的股票由内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Immunome</h2>
<div class="lb-trans"><h2>对 Immunome 的对冲基金看法</h2>
</div><p>An institutional investor recently raised its position in Immunome stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 44.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 46,821 shares of the company's stock after buying an additional 14,398 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.05% of Immunome worth $316,000 as of its most recent SEC filing. Institutional investors own 44.58% of the company's stock.</p>
<div class="lb-trans"><p>一位机构投资者最近增加了对 Immunome 股票的持仓。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Immunome, Inc.（纳斯达克：IMNM - 免费报告）的持股增加了 44.4%，根据其最近向证券交易委员会（SEC）的备案。该公司在本季度购买了额外的 14,398 股后，持有该公司 46,821 股股票。根据其最近的 SEC 备案，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.持有 Immunome 的股份占 0.05%，价值$316,000。机构投资者持有该公司 44.58% 的股票。</p>
</div><h2>Immunome Company Profile</h2>
<div class="lb-trans"><h2>Immunome 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.</p>
<div class="lb-trans"><p>Immunome, Inc.是一家生物技术公司，开发靶向癌症疗法。该公司的临床资产包括 AL102，一种正在进行的伽马分泌酶抑制剂，目前正在进行针对纤维瘤的三期临床试验；前临床资产包括 IM-1021，一种受体酪氨酸激酶样孤儿受体 1 和抗体药物偶联物，以及 IM-3050，一种针对成纤维细胞活化蛋白的放射性配体治疗；以及 IM-4320，一种抗 IL-38 免疫疗法候选药物。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Immunome</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Consider This Bank ETF Before The Fed Cuts Rate This Fall</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>Why These 3 Market-Beaters Are Backing Up Their Buyback Trucks</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>3 Stocks Every Value Investor Should Watch Out for Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Immunome 更好</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>在美联储今年秋季降息之前考虑这只银行 ETF</li>
<li>特殊目的收购公司（SPAC）你需要知道的事情</li>
<li>为什么这三只市场超越者正在支持他们的回购计划</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>每个价值投资者现在应该关注的 3 只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IMNM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunome Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Immunome 吗？</h2>
</div><p>Before you consider Immunome, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Immunome 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Immunome 并不在名单上。</p>
</div><p>While Immunome currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Immunome 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Immunome (IMNM) 将在周一公布季度财报